HC Wainwright Cuts Evolus (NASDAQ:EOLS) Price Target to $20.00

Key Points

• HC Wainwright has **lowered its price target** for Evolus (NASDAQ:EOLS) from **$27.00 to $20.00**, while maintaining a "buy" rating, indicating a potential upside of **124.47%** from the current price.
• Other analysts have set varying price targets, with BTIG Research initiating coverage at **$21.00** and Needham & Company reaffirming a **$22.00** price target, contributing to a consensus rating of **"Moderate Buy."**
• Recent insider trading saw CFO Sandra Beaver sell **6,494 shares** of Evolus, reflecting a **3.74%** decrease in her ownership, highlighting active insider trading amid shifting stock valuations.

Evolus (NASDAQ:EOLS - Free Report) had its target price reduced by HC Wainwright from $27.00 to $20.00 in a research report report published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

EOLS has been the subject of several other reports. Needham & Company LLC reissued a "hold" rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday. BTIG Research began coverage on shares of Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $21.25.

Evolus Stock Performance

Shares of NASDAQ EOLS traded down $0.17 during trading on Wednesday, hitting $5.90. 2,722,368 shares of the company traded hands, compared to its average volume of 1,984,819. Evolus has a 1 year low of $5.85 and a 1 year high of $17.82. The company has a 50-day moving average price of $9.25 and a 200-day moving average price of $11.12. The company has a quick ratio of 2.16, a current ratio of 2.27 and a debt-to-equity ratio of 22.00.

Insider Buying and Selling at Evolus

In other Evolus news, CFO Sandra Beaver sold 6,494 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $10.02, for a total value of $65,069.88. Following the transaction, the chief financial officer owned 167,089 shares in the company, valued at $1,674,231.78. The trade was a 3.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rui Avelar sold 3,385 shares of the business's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $9.87, for a total transaction of $33,409.95. Following the completion of the transaction, the insider owned 359,082 shares in the company, valued at $3,544,139.34. This represents a 0.93% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 153,571 shares of company stock valued at $1,537,090 in the last quarter. Company insiders own 5.90% of the company's stock.

Hedge Funds Weigh In On Evolus

A number of institutional investors have recently added to or reduced their stakes in EOLS. Tang Capital Management LLC boosted its stake in shares of Evolus by 3.1% during the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock valued at $55,171,000 after buying an additional 150,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in Evolus by 2.0% during the 1st quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company's stock worth $38,906,000 after acquiring an additional 62,664 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in Evolus by 10.8% during the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company's stock worth $34,557,000 after acquiring an additional 305,300 shares in the last quarter. Caligan Partners LP increased its position in shares of Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock worth $29,724,000 after purchasing an additional 498,900 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Evolus by 1.7% in the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company's stock valued at $16,746,000 after purchasing an additional 23,605 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.